Talquetamab and Belantamab for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination works better than using one drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults over 18 with multiple myeloma that has returned or is not responding to at least one prior therapy
- You must have tried treatments including an immunomodulator, a proteasome inhibitor, and a CD38-targeted drug
- Your cancer must be measurable (by blood tests, urine tests, or imaging)
- You need to have adequate kidney, liver, and blood cell counts as defined by the study
- You must agree to use effective contraception if needed during and for a period after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
This trial tests giving an immunotherapy drug (talquetamab) before CAR T-cell therapy (cilta-cel) to see if it helps people with multiple myeloma that has come back or stopped responding to other treatments.
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
This study looks at how well a treatment combining belantamab with other drugs works for patients whose multiple myeloma has come back. It may be an option if you have already received this drug combination on a compassionate use basis.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.